Sickle cell drug hits fast track
Sickle cell drug hits fast track
A purified poloxamer intravenous drug in Phase III trials as Flocor by CytRx Corp. in Atlanta has been granted fast-track status by the Food and Drug Administration for its success in clinical trials at alleviating the vaso-occlusive acute pain associated with sickle cell anemia.
The drug won’t cure the genetically inherited disease, but it is being hailed as a potential step in that direction for its ability to counter the disease-causing breakdown of hemoglobin in red blood cells, which causes the cells to become rigid and inflexible, which in turn impedes blood flow and causes acute pain.
CytRx expects to file a New Drug Application for Flocor by the end of this year.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.